Response to "letter concerning: Clewell (2019) incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene." (UIHT-2020-0053)

Inhal Toxicol. 2020 Aug;32(9-10):369-371. doi: 10.1080/08958378.2020.1817199. Epub 2020 Sep 8.

Authors

H J Clewell 3rd¹, J L Campbell¹, C Van Landingham², A Franzen², M Yoon³, D E Dodd⁴, M E Andersen⁴, P R Gentry³

Affiliations

¹ Research Triangle Park, Ramboll US Corporation, Charlotte, North Carolina, USA.
² Ramboll US Corporation, Monroe, Louisiana, USA.
³ ToxStrategies, Inc., Cary, North Carolina, USA.
⁴ Research Triangle Park, The Hamner Institutes for Health Sciences, North Carolina, USA.

PMID: 32900235
DOI: 10.1080/08958378.2020.1817199

No abstract available

Publication types

Letter
Comment

MeSH terms

Chloroprene*
Models, Biological
Risk Assessment

Substances

Chloroprene